argenx SE (ARGX)
1028.51
-3.15
(-0.31%)
USD |
NASDAQ |
Sep 01, 16:00
1028.68
+0.17
(+0.02%)
After-Hours: 20:00
argenx Cash from Operations (Annual) : 850.49M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 850.49M |
| December 31, 2024 | 28.85M |
| December 31, 2023 | -328.08M |
| December 31, 2022 | -850.13M |
| December 31, 2021 | -603.26M |
| December 31, 2020 | -393.09M |
| December 31, 2019 | 156.75M |
| December 31, 2018 | -61.90M |
| Date | Value |
|---|---|
| December 31, 2017 | -40.80M |
| December 31, 2016 | 11.81M |
| December 31, 2015 | -15.29M |
| December 31, 2014 | -6.762M |
| December 31, 2013 | -7.793M |
| December 31, 2012 | -10.32M |
| December 31, 2011 | -4.055M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Autolus Therapeutics Plc | -284.23M |
| Akari Therapeutics Plc | -10.59M |
| Forte Biosciences, Inc. | -50.88M |
| Evaxion AS | -6.645M |
| DBV Technologies SA | -121.56M |